GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (FRA:BPXA) » Definitions » Cyclically Adjusted PB Ratio

Bellicum Pharmaceuticals (FRA:BPXA) Cyclically Adjusted PB Ratio : 0.01 (As of Jun. 19, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Bellicum Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-19), Bellicum Pharmaceuticals's current share price is €0.163. Bellicum Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was €23.34. Bellicum Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.01.

The historical rank and industry rank for Bellicum Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Bellicum Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 0.04. The lowest was 0.01. And the median was 0.01.

FRA:BPXA's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.665
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Bellicum Pharmaceuticals's adjusted book value per share data for the three months ended in Sep. 2023 was €-2.665. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €23.34 for the trailing ten years ended in Sep. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Bellicum Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Bellicum Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellicum Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Bellicum Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bellicum Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.01 0.02 0.01

Competitive Comparison of Bellicum Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Bellicum Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellicum Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bellicum Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Bellicum Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Bellicum Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Bellicum Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.163/23.34
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bellicum Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Bellicum Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-2.665/129.8595*129.8595
=-2.665

Current CPI (Sep. 2023) = 129.8595.

Bellicum Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201312 -20.906 98.326 -27.611
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 -12.147 100.428 -15.707
201412 58.931 99.070 77.246
201503 64.929 99.621 84.637
201506 59.694 100.684 76.992
201509 55.847 100.392 72.240
201512 51.817 99.792 67.429
201603 46.728 100.470 60.397
201606 41.957 101.688 53.581
201609 37.185 101.861 47.406
201612 33.714 101.863 42.980
201703 40.456 102.862 51.074
201706 32.901 103.349 41.341
201709 26.018 104.136 32.445
201712 21.489 104.011 26.829
201803 15.969 105.290 19.695
201806 22.224 106.317 27.145
201809 18.278 106.507 22.286
201812 13.817 105.998 16.927
201903 10.010 107.251 12.120
201906 5.799 108.070 6.968
201909 0.225 108.329 0.270
201912 -4.711 108.420 -5.643
202003 -1.285 108.902 -1.532
202006 -8.562 108.767 -10.222
202009 -8.059 109.815 -9.530
202012 -0.247 109.897 -0.292
202103 -1.299 111.754 -1.509
202106 -1.408 114.631 -1.595
202109 -1.231 115.734 -1.381
202112 2.561 117.630 2.827
202203 1.838 121.301 1.968
202206 1.542 125.017 1.602
202209 0.879 125.227 0.912
202212 0.221 125.222 0.229
202303 -1.035 127.348 -1.055
202306 -2.123 128.729 -2.142
202309 -2.665 129.860 -2.665

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bellicum Pharmaceuticals  (FRA:BPXA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Bellicum Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellicum Pharmaceuticals (FRA:BPXA) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098
Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.

Bellicum Pharmaceuticals (FRA:BPXA) Headlines

No Headlines